Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises SEB in conjunction with co-operation with and investment in Leneo
Mandate

Vinge advises SEB in conjunction with co-operation with and investment in Leneo

June 20, 2022 IT, Telecommunications and Outsourcing M&A

Vinge has advised SEB in connection with the commencement of a strategic co-operation with and through SEB Venture Capital becoming a stakeholder in the Danish tech company, Leneo.

Leneo has developed a platform which assists companies to transfer to new business models, in which they sell a service instead of products, and where the product is included together with complementary services.

Vinge’s team primarily consisted of  Eva Fredrikson, Johan Winnerblad, Lisa Hörnqvist, Trine Osen Bergqvist and Carl Fredrik Wachtmeister.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024